The Brain Tumour Charity grants WINDOW Consortium £1.5 million for new research into combination therapies to treat brain cancer

The Dutch/British consortium will study glioblastoma

The Brain Tumour Charity grants WINDOW Consortium £1.5 million for new research into combination therapies to treat brain cancer

Glioblastoma.jpgChristaras A
MRI of person with a glioblastoma

The Dutch/British WINDOW Consortium has been awarded a grant of £1.5 million (€1.75 million) by the Brain Tumour Charity (UK) for research into Glioblastoma.

This unique collaboration will establish an international scientific network to generate more effective combination therapies against this deadly cancer, which has so far proved intransigent to any treatment. WINDOW will test many drug combinations to target different cells within each individual patient's tumour. By experimentally testing up to 100 combinations of drugs which already have clinical approval, WINDOW aims to accelerate the development of new treatments for Glioblastoma.

“This grant from the Brain Tumour Charity enables our international team to mount a direct attack on this deadly disease."

Research leader Bart Westerman from VU University Medical Centre, Amsterdam

Glioblastoma is the most common and malignant form of brain cancer. Each year, around 3,200 patients are diagnosed with this disease in the UK and the Netherlands. Despite improving knowledge of its genetic causes, it remains stubbornly incurable, with current treatment schedules resulting in an average survival of 12 months from diagnosis. Part of the poor prognosis is due to tumour heterogeneity: different parts of the tumour have different characteristics and will respond differently to therapy. As a result, a particular treatment may kill some of the tumour cells, while others cells continue to grow.

The researchers within the Consortium now aim to provide a solution to this problem by examining the links between intra-tumour molecular heterogeneity and combinatorial drug efficacy. Glioblastoma cells from individual patients will be established in the laboratory of Colin Watts at Addenbrooke's Hospital, part of Cambridge University Hospitals. These will then be passed to Bart Westerman and Tom Würdinger at the VU University Medical Centre in Amsterdam for experimental testing of up to 100 combinations of drugs to identify drug-combinations with broad clinical applicability, while maintaining specificity for cellular subtypes. Drug combinations that are effective in cell culture will subsequently also be tested in animal models in Amsterdam.

Data showing most promise for glioblastoma treatment will be assembled, annotated and distributed worldwide as a Glioblastoma Drug Bank by IOTA Pharmaceuticals, led by David Bailey and Fredrik Svensson in Cambridge. In further studies, Emmanouil Metzakopian's team from the Wellcome Trust Sanger Institute (UK) will use new CRISPR-Cas9 genome editing technology to identify new molecular targets, contributing to drug resistance in the same patient-derived tumour cells.

The creation of such an integrated approach for effective treatment is expected to accelerate the development of new combination therapies and to seed development of new molecular approaches to treat glioblastoma.

“Our strategy will combat this cancer from a cellular point of view. Novel drug therapies coming from specialties such as immuno-oncology will further complement the WINDOW approach.”

Research leader Bart Westerman from VU University Medical Centre, Amsterdam

Notes to Editors
Further information

The acronym "WINDOW" stands for ‘Window for Improvement for Newly Diagnosed patients by Overcoming disease Worsening’.

Further information on WINDOW is available through its website at, which will be used as an open access portal for sharing data and methods.


The WINDOW consortium consists of teams led by the Dutch Researchers Bart Westerman and Tom Würdinger (VUmc Cancer Centre Amsterdam/Brain Tumour Centre Amsterdam) and the Cambridge, UK, researchers Colin Watts (Addenbrooke's Hospital, Cambridge University Hospitals), Emmanouil Metzakopian (Wellcome Trust Sanger Institute) and David Bailey and Fredrik Svensson (IOTA Pharmaceuticals Ltd).

Selected Websites
Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

500,000 whole human genomes will be a game-changer for research into human diseases
Following on from a successful pilot at the Sanger Institute, we are leading a project to sequence the genomes of all UK Biobank volunteers to power the next wave of genetic and health research
Brown trout genome will help explain species' genetic superpowers
Eagerly awaited reference genome will allow conservationists to understand how the fish adapts to marine and freshwater environments
LifeLab 2019 – discovery on your doorstep with an exciting programme of free events and activities
LifeLab has launched an exciting programme of events for Friday 27 and Saturday 28 September 2019, transforming parts of Cambridge, Peterborough and Ely into discovery zones for the weekend